ArticleFrontiers in microbiology2011
Pseudomonas aeruginosa: resistance to the max.
Article in Frontiers in microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06811727 (CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections), which is not on this map. Cited by 443 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections: A Single-centre Randomized Open-label Trial (ZAVICONT)
Who cites it
443 citing papers in PubMed, 1 synthesis or guideline pooled it, 926 citations in OpenAlex.
- Prevalence of antimicrobial resistance in equine-associated Pseudomonas aeruginosa: a systematic review and meta-analysis.BMC veterinary research · 2025Pooled it
- Trial
- From Tradition to Bioactivity: Chemical and Biological Evaluation of a Reformulated Algerian Ancestral Soap Enriched With Lavandula dentata L. Essential Oil.Chemistry & biodiversity · 2026Article
- Effects of Magnesium and Calcium Cations on Antibiotic Susceptibility ofAntibiotics (Basel, Switzerland) · 2026Article
- Epidemiology, risk factors and clinical outcomes of multidrug-resistantJournal of thoracic disease · 2026Article
- Prevalence and Antimicrobial Resistance ofInfectious disease reports · 2026Article
- Pepholin, a bacteriophage holin-derived antimicrobial peptide with membrane-disruptive activity and therapeutic efficacy in MDRRSC advances · 2026Article
- Occurrence and Distribution of Environmental Pseudomonas aeruginosa From Hospitals in Bangladesh Reveals Diverse Strain Families, Multidrug Resistance, and Biofilm Formation.Environmental microbiology reports · 2026Article
- Calcium regulation ofApplied and environmental microbiology · 2026Article
- Antibiotic resistance mechanisms and global resistance patterns of Pseudomonas aeruginosa in microbial keratitis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Potentiating Effect of Beauvericin on Colistin, a Last Resort Antibiotic in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Enhancing Allicin Purity and Gastrointestinal Bioactivity Profile of Garlic Extracts Through Optimized Supercritical-COFoods (Basel, Switzerland) · 2026Article
- Non-canonical double-stranded DNA break repair in Pseudomonas aeruginosa includes LigD-independent non-homologous end joining.Nucleic acids research · 2026Article
- In vitro exposure to non-antipseudomonal antibiotics (NAPA) induces Pseudomonas aeruginosa resistance to antipseudomonal antibiotics (APA).The Journal of antimicrobial chemotherapy · 2026Article
- Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies.Archives of microbiology · 2026Review
- Forecasting Multitrait Resistance Evolution under Antibiotic Stress.Molecular biology and evolution · 2026Article
- Clearance of hypermutator XDRASM case reports · 2026Article
- Activity of cefepime/enmetazobactam against highly multidrug-resistant bacterial isolates recovered from war-associated wounds in Ukraine.JAC-antimicrobial resistance · 2026Article
- Antibiotic resistance of Pseudomonas aeruginosa strains-intracellular metabolomics analysis.The Journal of antimicrobial chemotherapy · 2026Article
- Harnessing silica-coated silver nanoparticles for combating multidrug-resistant Pseudomonas aeruginosa.Applied microbiology and biotechnology · 2026Article
383 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is intrinsically resistant to a variety of antimicrobials and can develop resistance during anti-pseudomonal chemotherapy both of which compromise treatment of infections caused by this organism. Resistance to multiple classes of antimicrobials (multidrug resistance) in particular is increasingly common in P. aeruginosa, with a number of reports of pan-resistant isolates treatable with a single agent, colistin. Acquired resistance in this organism is multifactorial and attributable to chromosomal mutations and the acquisition of resistance genes via horizontal gene transfer. Mutational changes impacting resistance include upregulation of multidrug efflux systems to promote antimicrobial expulsion, derepression of ampC, AmpC alterations that expand the enzyme's substrate specificity (i.e., extended-spectrum AmpC), alterations to outer membrane permeability to limit antimicrobial entry and alterations to antimicrobial targets. Acquired mechanisms contributing to resistance in P. aeruginosa include β-lactamases, notably the extended-spectrum β-lactamases and the carbapenemases that hydrolyze most β-lactams, aminoglycoside-modifying enzymes, and 16S rRNA methylases that provide high-level pan-aminoglycoside resistance. The organism's propensity to grow in vivo as antimicrobial-tolerant biofilms and the occurrence of hypermutator strains that yield antimicrobial resistant mutants at higher frequency also compromise anti-pseudomonal chemotherapy. With limited therapeutic options and increasing resistance will the untreatable P. aeruginosa infection soon be upon us?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.